Immune checkpoint inhibitor therapy (ICT), targeting cytotoxic T-lymphocyte–associated-antigen-4 (CTLA-4) and/or programmed cell death protein 1 (PD-1), results in durable remissions in patients with previously incurable cancers (1). The gene discussed is PDCD1; the disease is cancer.